# EDGAR Filing Document

**Accession Number:** 0001906324
**File Stem:** 0001906324-26-000028
**Filing Date:** 2026-6
**Character Count:** 30724
**Document Hash:** 365c5fc24f98a8c61822c093c0937b3c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001906324-26-000028.hdr.sgml**: 20260623

**ACCESSION NUMBER**: 0001906324-26-000028

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20260622

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260623

**DATE AS OF CHANGE**: 20260623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QuidelOrtho Corp
- **CENTRAL INDEX KEY:** 0001906324
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 874496285
- **FISCAL YEAR END:** 0101

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41409
- **FILM NUMBER:** 261111015

**BUSINESS ADDRESS:**
- **STREET 1:** 9975 SUMMERS RIDGE ROAD
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 552-1100

**MAIL ADDRESS:**
- **STREET 1:** 9975 SUMMERS RIDGE ROAD
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Coronado Topco, Inc.
- **DATE OF NAME CHANGE:** 20220124

?xml version='1.0' encoding='ASCII'? qdel-20260622

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **June 22, 2026**

    

**QUIDELORTHO CORPORATION**

(Exact name of Registrant as specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41409** | **87-4496285** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**9975 Summers Ridge Road, San Diego, California 92121** 

(Address of principal executive offices, including zip code)

**(858) 552-1100** 

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 Par Value | QDEL | The Nasdaq Stock Market |

---

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |
| Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  | ☐ |

---

------

**Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

***Announcement of New Chief Financial Officer***

The Board of Directors of QuidelOrtho Corporation (the "Company") has appointed Micah Young to serve as the Company's Chief Financial Officer and principal financial officer, effective as of July 6, 2026 (the "Effective Date"). Mr. Young will succeed Joseph M. Busky, who previously announced his plans to retire, as disclosed in the Company's Current Report on Form 8-K filed on February 13, 2026. Mr. Busky has agreed to continue to serve in his current role through the Effective Date, and in connection therewith, is expected to enter into a transition and retirement agreement to provide for the smooth and orderly transition of his duties.

Mr. Young (age 48) most recently served as Executive Vice President and Chief Financial Officer of Masimo Corporation (formerly, Nasdaq: MASI), a global medical technology company, from October 2017 until Masimo's acquisition by Danaher Corporation in June 2026. In this role, Mr. Young was responsible for finance and accounting functions, as well as investor relations, information technology and corporate development. From 2009 to 2017, Mr. Young served in various finance roles at NuVasive, Inc. (formerly, Nasdaq: NUVA), a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders, including most recently as Vice President, Finance. From 2002 to 2009, Mr. Young held various accounting and finance positions with Zimmer Holdings, Inc., a company focused on the design, development, manufacture and marketing of orthopedic reconstructive, spinal and trauma devices, dental implants and related surgical products. Prior to his time at Zimmer Holdings, Inc., Mr. Young was an auditor at Deloitte & Touche LLP from 2000 to 2002. He holds a B.S. in Accounting and Criminal Justice from Indiana Wesleyan University and is a Certified Public Accountant (inactive).

***Employment Offer Letter and Agreements with Micah Young***

The Company and Mr. Young have entered into an employment offer letter, dated June 22, 2026 (the "Offer Letter"), pursuant to which Mr. Young is entitled to receive (i) an annual base salary of $750,000 and (ii) an annual target cash bonus opportunity of 100% of base salary. Mr. Young will also receive a cash sign-on bonus in the amount of $500,000, and a one-time inducement sign-on grant of restricted stock units ("RSUs") with a grant date value of $6,500,000, which is subject to vesting in equal annual installments over a three-year period. The Company intends to grant the inducement RSUs to Mr. Young in accordance with and in reliance upon Nasdaq Listing Rule 5636(c)(4). Mr. Young will be eligible to receive future equity grants, with an expected 2027 grant value of $5,000,000, consisting of (a) 50% time-based RSUs, and (b) 50% non-qualified stock options. Mr. Young will also be eligible for health, welfare and other benefits afforded Company executive officers, as well as reimbursement of reasonable legal fees incurred in connection with the negotiation of the Offer Letter.

Under the Offer Letter, Mr. Young will also receive severance and change in control protection consistent with other arrangements with Company executive officers pursuant to a Severance and Change in Control Agreement (the "Severance and CIC Agreement"), substantially in the form as filed as Exhibit 10.15 to the Company's Annual Report on Form 10-K for the year ended December 28, 2025 filed on February 19, 2026 (the "Annual Report"). The Severance and CIC Agreement provides for the payment of severance benefits if (1) the executive's employment is terminated without Cause (as defined therein) more than 30 days prior to or more than two years following a Change in Control (as defined therein) (a "Non-CIC Qualifying Termination") or (2) the executive's employment is terminated within two years following or 30 days prior to a Change in Control (a "CIC Qualifying Termination") for any reason other than the executive's voluntary resignation, the executive's death or permanent disability, or our termination of the executive for Cause. In the case of a Non-CIC Qualifying Termination, Mr. Young would generally be entitled to (i) a severance payment equal to two times the sum of his annual base salary and bonus; (ii) continued benefits coverage for up to two years; and (iii) payment of $25,000 to help defray legal, tax and accounting fees, executive outplacement services and other costs (collectively, the "Severance Benefits"). In the event of a CIC Qualifying Termination, Mr. Young would generally be entitled to the Severance Benefits, as well as full vesting and acceleration of all unvested RSUs, stock options and other equity awards.

Under the Offer Letter, Mr. Young will also be provided with indemnification consistent with other arrangements with Company executive officers pursuant to an Indemnification Agreement, substantially in the form as filed as Exhibit 10.14 to the Annual Report, and he will be subject to the Company's standard form of Confidential Information, Inventions, Non-Solicitation, and Non-Competition Agreement.

The foregoing summary of the terms and conditions of Mr. Young's employment does not purport to be complete and is qualified in its entirety by reference to the full text of the Offer Letter, a copy of which is attached hereto as Exhibit 10.1 to this Current Report on Form 8-K ("Form 8-K") and is incorporated herein by reference.

There is no arrangement or understanding between Mr. Young and any other person pursuant to which he was appointed as an officer of the Company; there is no family relationship between Mr. Young and any of the Company's directors or other

------

executive officers; and Mr. Young is not a party to any transactions of the type that would require disclosure under Item 404 of Regulation S-K.

***Agreements with Joseph Busky***

As indicated above, Mr. Busky is expected to enter into a transition and retirement agreement to provide for the smooth and orderly transition of Mr. Busky's duties as Chief Financial Officer. During such transition period, for the six months following the Effective Date, the Company will pay Mr. Busky at an annual base salary rate of $340,000. Thereafter, Mr. Busky has agreed to serve as a special advisor to the Company's Chief Executive Officer for a period of up to twenty-four months, at an annual base salary rate of $100,000. Mr. Busky will be entitled to participate in and receive payments with respect to the Company's 2026 annual cash bonus plan, but shall not be entitled to participate in or receive payments with respect to any annual cash bonus plans after calendar year 2026. Mr. Busky will remain eligible for employee benefits during his service as a special advisor, other than future annual bonus and equity grant opportunities. Mr. Busky's equity awards will continue to remain outstanding and vest under the existing terms and conditions set forth in the governing plan documents and applicable equity agreements through the end of his service as a special advisor.

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.** 

On June 23, 2026, the Company issued a press release announcing the appointment of Mr. Young as Chief Financial Officer. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.

The following exhibits are filed or furnished with this Form 8-K:

---

| | |
|:---|:---|
| <u>Exhibit Number</u> | <u>Description of Exhibit</u> |
| 10.1 | <u>[Employment Offer Letter, dated June](qdel62320268-kex101.htm)[22](qdel62320268-kex101.htm)[, 2026, between QuidelOrtho Corporation and Micah Young.](qdel62320268-kex101.htm)</u> |
| 99.1 | <u>[Press release issued by QuidelOrtho Corporation, dated June](qdel62320268-kex991.htm)[23](qdel62320268-kex991.htm)[, 2026.](qdel62320268-kex991.htm)</u> |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 23, 2026

---

| | |
|:---|:---|
| **QUIDELORTHO CORPORATION** | **QUIDELORTHO CORPORATION** |
| By: | /s/ Nathaniel B. Sisitsky |
| Name: | Nathaniel B. Sisitsky |
| Its: | Chief Legal Officer and Corporate Secretary |

---

## Exhibit 10.1

**Exhibit 10.1**

![picture1.jpg](picture1.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

June 22, 2026

Dear Micah,

We are excited to offer you this exceptional opportunity for employment from QuidelOrtho Corporation (the "Company") in the position of **Chief Financial Officer,** reporting to the Chief Executive Officer of the Company ("CEO"). In your role as Chief Financial Officer , you will perform duties and responsibilities that are reasonable and consistent with such position as may be assigned to you from time to time by the CEO. This is a full-time, exempt position that requires at least 40 hours of work per week. Pending your satisfactory completion of the Company's pre-employment requirements, background checks, and the Company's final assessment of your suitability for this position, your anticipated start date is July 6, 2026.

We are confident you will find your new role to be one in which you can make significant contributions to the Company as well as enhance your work experience and abilities. This offer and your employment relationship with the Company, of course, are and will remain "at will," and are subject to the terms and conditions of this letter, as well as to the Company's standard hiring and personnel policies, rules and practices.

The Company office address and telephone number for the Company are 9975 Summers Ridge Road, San Diego, CA 92121. (858) 552-1100.

The following further represents our offer to you:

**Compensation** 

Your initial annualized base salary, which will be paid bi-weekly unless otherwise determined by state or local law, will be $750,000. You will receive payment of your earned compensation at the employee address the Company has on file for you or your check will be available for you at a site in your local geography. Direct deposit can also be established during onboarding. Also, keep in mind that an "exempt" position means you are paid for all the job duties you perform and not by the hour, and your salary will compensate you for all the hours you work. Accordingly, you will not be eligible to earn or be paid overtime pay. Your work hours also may vary from week to week depending on the Company's business needs. Your next annual merit review will be in 2027.

**Global Bonus Plan** 

The Company maintains highly competitive, compensation programs intended to provide you with an incentive to help you achieve annual targeted results. Under current guidelines, your position makes you eligible for the annual Global Bonus Plan (GBP), pursuant to the terms and conditions of the plan, with a target bonus opportunity of 100%. GBP awards are provided at the Company's discretion, based primarily on company performance. This eligibility begins in the current calendar year if your hire date is prior to October 1st. We will pro-rate your GBP award eligibility for Fiscal Year 2026. Compensation levels, incentive plans, and bonus awards are subject to change at the Company's discretion.

The amount of any bonus awards is at the management's sole discretion and may be contingent upon the performance of the Company, the performance criteria defined by the

Page 1 of 5

------

Company, the terms of its incentive and compensation plans, and your length of service during the applicable performance year.

**Long-Term Equity Incentive Plan** 

*One-Time Sign-on Equity Grant* 

Should the Company determine you have passed your pre-employment contingencies and hires you, you are also eligible to participate in the Company's Long-term Equity Incentive Plan ("Plan") in accordance with the terms and conditions of the Plan. You will receive an inducement sign-on equity grant with a target value of $6,500,000, vesting one-third per year. The effective date of your equity grants described herein is expected to be the 15th day of the month following your Start Date (the "Grant Date"). Accordingly, based on your expected Start Date of July 6, 2026, the Grant Date for your inducement sign-on equity grants would be July 15, 2026. The number of shares is dependent upon the stock valuation and the Grant Date and may be adjusted by the Company based on stock value changes. The total value of this award is expected to be granted in the form of time- based RSUs which vests in equal annual installments over a three-year period from the grant date. The award will be subject to the Plan and the applicable award agreement, including vesting restrictions that will be set forth in a separate agreement to be provided to you.

*One-Time Sign-on Cash Bonus* 

You will also receive a one-time sign-on cash bonus of $500,000.00 (subject to all applicable taxes). that will be paid within 30 days after your Start Date,

*Annual LTI Grant* 

You will be eligible to receive future equity grants under the Plan in accordance with the terms and conditions of the Plan and applicable award agreement(s) and subject to approval by the Board (or its compensation committee). You are expected to receive a 2027 equity grant of $5,000,000 (balanced mix of RSUs and NQSOs) during the normal annual grant award cycle of the Company (which is usually in April). Any LTI grants will be subject to the Plan and applicable award document(s).

Note: All compensation, incentive or bonus awards, and benefits referred to in this letter or otherwise provided by the Company are subject to your satisfactory job performance, conduct and attendance. Also, the amount of bonus awards is at the Board's sole discretion and is contingent upon the performance of the Company, the performance criteria defined by the Company, the terms of its incentive and compensation plans, and your length of service during the applicable performance year. All salary, performance-based pay awards, bonuses, allowances, and other forms of compensation and incentives referred to in this letter will be considered normal income and will be subject to applicable Federal, State and Local income taxes, withholdings and deductions.

**<u>Severance and Change in Control Agreement</u>**

You will be provided with severance and change in control protection consistent with other arrangements for those eligible at the executive officer level. You are being provided with a copy of the Severance and Change in Control Agreement (the "Severance and Change in Control Agreement") with this offer letter. In the event a Severance Payment (as defined in the Severance and Change in Control Agreement) becomes payable during your first two years of employment, your Bonus Increment (as defined in the Severance and Change in Control Agreement) shall be the greater of (i) the annualized average of cash bonuses and cash incentive compensation payments paid to you during such two year period and (ii) your target cash bonus opportunity under the GBP for the year of termination.

Page 2 of 5

------

**<u>Indemnification Agreement</u>**

You will be provided with indemnification consistent with other arrangements for those eligible at the executive officer level. You are being provided with a copy of the Indemnification Agreement with this offer letter.

**Vacation** 

Vacation for employees in an Executive level position or for remote exempt employees is unlimited. There is no accrual account and instead you take vacation in consultation with your supervisor as your work allows. Members of the leadership team take an average of four weeks of vacation per year. You must notify the Company of all your vacation time off in advance of taking the time off. The Company reserves the right to deny a vacation request based on business needs, or to disallow further vacation in a given year if the Company determines you have taken too much vacation already.

**Benefits** 

Our flexible benefits program includes medical, dental, life, and accident coverage for employees and qualified dependents, for which coverage begins on the first day of employment. In addition, the Company has a 401K Savings Plan that employees may choose to participate in. Eligibility and coverage are determined and governed exclusively by the underlying plan documents. A Benefits Summary is being delivered to your Candidate Home Page with this offer.

**Invitation to Self-Identify** 

As a Federal contractor subject to Section 503 of the Rehabilitation Act of 1973, the Vietnam-era Veterans Readjustment Assistance Act of 1974 and the Veterans Employment Opportunity Act of 1998, we are required to extend to applicants a post-offer invitation to self-identify as a Vietnam-era veteran, or veteran covered by the Veterans Employment Opportunities Act of 1998. Providing this information is voluntary and will be kept confidential in accordance with the law. Choosing not to provide it will not have an adverse impact on employment. This information will be used only in accordance with our equal employment opportunity policy.

**Employee Arbitration Agreement** 

As a condition of being hired and employed by the Company, the Company requires all new hires to enter into an Arbitration Agreement. Except as otherwise provided in the Arbitration Agreement, the Arbitration Agreement is the exclusive means for resolving and attempting to resolve disputes between you and the Company, both during or after your employment with the Company. You are being provided with a copy of the Arbitration Agreement with this offer letter. If you accept this conditional offer and you are hired, you must agree to and sign the Arbitration Agreement by or before your first day of employment with the Company and provide the signed agreement to the Company.

**At-Will Employment** 

This employment offer is only for "at-will" employment with the Company. The Company also maintains an employment-at-will relationship with its employees. This means that both you and the Company retain the right to terminate the employment relationship at any time, with or without notice or cause, and for any reason or no reason not contrary to law. As for all the Company's job candidates, for candidates in South Carolina—and pursuant to S.C. Code Ann. 41-1-110--this offer letter shall not create an express or implied contract of employment, and any employment with the Company will be at-will.

**OFFER REQUIREMENTS** 

This offer and, if hired, your subsequent employment, are contingent upon your accurately, honestly, and satisfactorily completing all pre-employment forms, requirements and

Page 3 of 5

------

conditions, submitting all requested information, and agreeing to and meeting all necessary requirements for employment. Failure to do so can render this offer or any employment begun null and void, and result in the Company not hiring you or terminating any employment already started.

This offer is contingent upon satisfactory results of the following:

• **Background check**

• **Reference checks if applicable**

This offer is also contingent upon accurate, honest and satisfactory completion and submission of the following:

• **Background Check Release Forms:** You will receive a "Request for Pre-Employment Screening" e- mail notification regarding your background check, which you must complete online.

• **Work Authorization (I-9 Documentation):** Employers must verify the employment eligibility and identity of all new employees. In accordance with the Immigration Reform and Control Act, you must provide the Company with appropriate work authorization documents by or on your first day of employment.

**Agreement re Confidential Information, Inventions, Non-Solicitation, and Non-Competition** 

• **AGREEMENT RE CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION, AND NON-COMPETE:** As a condition of employment, you will be required to review and accept the Company's **AGREEMENT RE CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION, AND NON-COMPETITION.** You are being provided with a copy of the AGREEMENT with this offer letter. If you accept this conditional offer and you are hired, you must agree to and sign the AGREEMENT by or before your first day of employment with the Company and provide the signed AGREEMENT to the Company.

• In addition to requiring you to enter into the Agreement, we expect you to keep confidential and not disclose or use in your employment with us any trade secrets or confidential information you have obtained from your present or previous employer(s). We do not need or want their confidential or trade secret information.

This offer letter constitutes our complete offer. Any promises or representations, either oral or written, not contained in this letter and the documents referred to herein, are not valid, authorized, or binding on the Company.

Please note that we may review, adjust, modify, or suspend Company policies, compensation levels, incentive or bonus programs and awards, benefit plans, and any other practices or programs for business reasons at any time. Your eligibility will be determined per the standard terms and eligibility requirements of the policies, plans, and programs in effect at that time.

We are thrilled to welcome you to the team and are confident that your leadership will drive exceptional results in this pivotal role. Assuming you complete and meet our pre-employment conditions satisfactorily, we eagerly anticipate your acceptance of this exciting opportunity. Please signify your agreement to and acceptance of this offer of employment by replying to this message no later than June 22, 2026, and by entering your name and date in the Agreed & Accepted section below. If you have any questions concerning this offer, please don't hesitate to give me a call.

Page 4 of 5

------

Sincerely,

/s/ Lee Bowman

Lee Bowman – Chief Human Resources Officer,

on behalf of QuidelOrtho

---

| | | |
|:---|:---|:---|
| Agreed and Accepted: | /s/ Micah Young | June 22, 2026 |
| | Signature: (Micah Young) | Date |

---

Page 5 of 5

## Exhibit 99.1

**Exhibit 99.1**

![picture11.jpg](picture11.jpg)

![image.jpg](image.jpg)

**QuidelOrtho Appoints Micah Young as Chief Financial Officer** 

*Seasoned medical technology finance executive brings more than two decades of leadership at global public companies*

June 23, 2026

**SAN DIEGO, CA —** QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M. Busky, who previously announced his retirement as Chief Financial Officer and will serve in an advisory role to support a smooth transition.

"Micah is an accomplished public-company CFO with deep medical technology expertise and a strong track record of improving financial performance, strengthening cash flow and driving disciplined execution," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "His leadership across business strategy, capital allocation, investor relations and financial operations will be valuable as we execute our priorities to improve profitability, enhance cash generation and create long-term shareholder value. We are excited to welcome Micah to the QuidelOrtho leadership team."

Mr. Blaser added, "We thank Joe for his leadership and many contributions to QuidelOrtho. He has played an important role in strengthening our financial discipline and guiding the Company through a period of significant transformation. We appreciate his support of a seamless transition and wish him the very best."

Mr. Young most recently served as Executive Vice President and Chief Financial Officer of Masimo Corporation, a global medical technology company. He joined Masimo as CFO in 2017 and helped lead the company through a period of strategic transformation, operational improvement, disciplined capital allocation, enhanced investor engagement and significant transaction activity. Previously, he held progressively senior finance roles at NuVasive, Inc. and finance and accounting roles at Zimmer Holdings, Inc., after beginning his career at Deloitte & Touche LLP. Mr. Young holds a Bachelor of Science in Accounting and Criminal Justice from Indiana Wesleyan University and is a Certified Public Accountant (inactive).

"I am honored to join QuidelOrtho at an important point in the Company's evolution," said Mr. Young. "QuidelOrtho has a strong global portfolio, a meaningful mission and clear opportunities to enhance execution and performance. I look forward to working with Brian, the Board and the

------

leadership team to strengthen operational discipline, support growth and create sustainable value for shareholders, customers and patients."

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit <u>quidelortho.com</u> and follow QuidelOrtho on LinkedIn, Facebook and X.

**About QuidelOrtho Corporation**

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:

Juliet Cunningham

Vice President, Investor Relations

<u>IR@QuidelOrtho.com</u>

Media Contact:

Stephanie Kleewein

Senior Corporate Communications and PR Manager

<u>media@QuidelOrtho.com</u>

SOURCE QuidelOrtho Corporation

<br>